Patrick J. Branigan

机构：Johnson & Johnson (United States) · ORCID：0000-0001-9741-9067

发表论文 100 篇 · 总被引 2889 次 · h-index 27

代表论文

• Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial (2019 · The Lancet · 被引 384)
• Biopsy and blood-based molecular biomarker of inflammation in IBD (2022 · Gut · 被引 124)
• Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study (2019 · Journal of Investigative Dermatology · 被引 106)
• Deep Learning Models Capture Histological Disease Activity in Crohn’s Disease and Ulcerative Colitis with High Fidelity (2023 · Journal of Crohn s and Colitis · 被引 51)
• The first‐in‐human study of CNTO 7160, an anti‐interleukin‐33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis (2020 · British Journal of Clinical Pharmacology · 被引 37)
• Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus (2020 · Arthritis & Rheumatology · 被引 28)